Semaglutide drugs such as ozapic and vegovi have exploded popularity in recent years due to diabetes control and their effectiveness in weight loss.
Research has detected additional benefits beyond those primary uses – but some negative side effects have also been revealed.
While the gastrointestinal issues are the most common side effects, the recent GLP-1 (Glucagon-like peptide-1) by the University of British Columbia is a class of agonist-drawings that include semaglutides-to the increasing risk of loss of children.
Bald in ‘new Botox’ for treatment of hair loss
Researchers analyzed data from 16 million patients of a health claim database, limiting it to 1,926 semglutide users and 1,348 users bopropian-nultrexone, 1,348 users of another type of weight-loss drug.
A recent study of the University of British Columbia has added a class of GLP-1 (Glucagon-like peptide-1) to the class of semaglutides-for the increasing risk of falling semaglutides. (Istock)
After adjusting to other factors, he found that the semaglutide users were more likely to experience hair loss than other groups.
This result of women was more likely, with double the risk of men.
‘Not surprising’
Researchers, an epidemicist of epultics and co-study writer of CEO in Vancouver, British Columbia, Canada. According to Mahayar Ataminon, the results were not surprised by the results.
“Hair loss (previous) was an important reports of hair loss and also reports of hair loss in clinical trials of drugs.”
Hair loss? Attestinal Health Issues? Dr. Nicole Saifier revealed smart fix
Dr. Patrick Davis, a bevarly hills plastic surgeon and hair restoration expert, agreed that the conclusions were not surprising.
In an interview with Fox News Digital, he said, “We have heard these anecdotes when patients have consulted us for the surgical restoration of their face after rapid weight loss.”
After adjusting to other factors, researchers found that the semaglutide users were likely to experience hair loss compared to other groups. (Istock)
“Hair growth (and loss) is very dependent on factors such as diet, essential vitamins, physical stress and genetics.”
The first three factors come to play during weight loss, he said- “And there is no exception to the semaglutide-driven loss.”
Previous studies have shown that the risk of hair loss may increase by induction of stress or affecting someone’s nutritional intake, the doctor said.
“Hair growth (and loss) is very dependent on factors such as diet, essential vitamins, physical stress and genetics.”
Davis said, “This study says that those who lose more than 20% of their body weight had higher hair loss rate, which did not.”
“This study suggests that it can be caused by suspected physical stress, which may be a symptom of such rapid weight loss.”
Long -term hair loss is not more likely, the doctor said, “provocative event” (weight loss and stress) often becomes normal because individuals reach their target weight.
Potential limits
The study had some limitations, the researcher Ataminon said.
They included the fact that it could not verify hair loss through medical records, but only identified the medical code for hair loss.
Women were more likely to experience semglutide -related hair loss, with double risk with men’s risk. (Istock)
Plastic surgeon, Davis, also stated that this research refers to another study in which Vagovi users had a risk of hair loss (3.3%) relative to the placebo group (1.4%).
“While this clearly shows an increased risk, 3.3% still has very few events,” he said.
Hair growth can slow down with this popular diet plan, studies show
This preliminary study, which was published in the preprint server Medrxiv, has not yet been reviewed.
Researchers wrote, “Future studies require detecting the relationship between semaglutide and hair loss.”
Doctors advice
People who experience hair loss while taking semaglutide drugs, they should consult with a dermatologist to determine if it is due to adverse effects of these drugs, iteminon advised.
“This is a relatively new adverse event and not much known about it,” he said. “The question about who is the highest risk and what hair loss will be revealed when the drug will be reverse in future studies.”
When contacted by Fox News Digital, the Novo Nordisk – Ozmpic and Vegovi’s manufacturer – confirmed that hair loss is an recognized risk for semaglutide, and is listed as a side effect in the product information. (Getty image)
Davis agreed, encouraging patients to have an open interaction with their doctor how they could take care of themselves.
“I believe that before taking any medicine, a patient should take into account any possible side effects,” he said.
Click here to get Fox News app
“While the rate of hair loss incidence is still low, it is a potential trade closed on which a patient should consider.”
Davis also recommends that his patients adopt a “hearty diet”, which includes fiber, protein, and nutritious foods to ensure proper nutrition while taking a semaglutide medicine.
People who experience hair loss while taking semaglutide drugs, they should consult a dermatologist to determine if this is due to the adverse effects of these drugs, a specialist advised by a specialist. (Istock)
“Not only can it help in hair loss, but even more importantly, a strong diet can curb the unwanted damage to the muscle mass that often occurs,” he said. “A proper diet, conservative timetable for weight loss, and plan for exercise while taking this medicine is necessary.”
Click here to sign up for our health newspaper
When contacted by Fox News Digital, the Novo Nordisk – Ozmpic and Vegovi’s manufacturer – confirmed that hair loss is an recognized risk for semaglutide, and is listed as a side effect in the product information.
The company spokesperson said, “In Vagovi’s clinical trials, hair loss was reported in 1.0% of the 2.5% vegovi-credited adult patients versus placebo-abused adult patients,” said the company’s spokesman.
“While the rate of hair loss incidence is still low, it is a potential trade closed on which a patient should consider.”
“Hair loss was reported more frequently in patients with overweight loss (20%), suggesting that the incidence of hair loss was potentially related to the magnitude of weight loss.”
The statement continued, “The safety of the patient is of great importance for Novo Nordisk.” “We are constantly monitoring the safety profile of our products and collaborating with the authorities to ensure the safety of the patient, including adequate information about hair loss.”
For more health articles, travel www.foxnews.com/health
The Journal article states that this study was funded by the Department of Internal Research Fund from the Department of Eye Sciences and Visual Sciences, British Columbia.
